Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULFOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULFOSE.
GANTRISIN vs SULFOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Sulfonamide antibiotic; inhibits bacterial dihydropteroate synthase, blocking folate synthesis and bacterial growth.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
Meningococcal meningitis: 100 mg/kg/day intravenously in 4 divided doses (maximum 6 g/day). For other infections: 2-4 g/day IV/IM in 3-4 divided doses.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 3-4 hours in patients with normal renal function; prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: ~90% as unchanged drug via glomerular filtration; biliary/fecal: <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic